Tumor accumulation of novel RES-avoiding liposomes.

@article{Oku1992TumorAO,
  title={Tumor accumulation of novel RES-avoiding liposomes.},
  author={N. Oku and Y. Namba and S. Okada},
  journal={Biochimica et biophysica acta},
  year={1992},
  volume={1126 3},
  pages={
          255-60
        }
}
For passive targeting of liposomes to tumor tissues, we earlier developed reticuloendothelial system (RES)-avoiding liposomes modified with a uronic acid derivative, palmityl-D-glucuronide (PGlcUA) (Namba, Y., Sakakibara, T., Masada, M., Ito, F. and Oku, N. (1990) Chem. Pharm. Bull. 38, 1663-1666). In this present study, we examined the blood clearance and biodistribution of PGlcUA-liposomes (dipalmitoylphosphatidylcholine/cholesterol/PGlcUA = 40:40:20 as a molar ratio) in normal and tumor… Expand
Anticancer therapy using glucuronate modified long-circulating liposomes.
  • Oku
  • Medicine
  • Advanced drug delivery reviews
  • 1999
Tumor imaging with technetium-99m-DTPA encapsulated in RES-avoiding liposomes.
Uptake of Long-Circulating Immunoliposomes, Directed Against Colon Adenocarcinoma Cells, by Liver Metastases of Colon Cancer
Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 19 REFERENCES
Glucuronate-modified liposomes with prolonged circulation time.
Inhibitory effect of cholesterol on the uptake of liposomes by liver and spleen.
Liposomes for the sustained drug release in vivo.
...
1
2
...